GLYATL2 is a mitochondrial acyltransferase that catalyzes the transfer of acyl groups to the N-terminus of glycine, producing N-acyl glycines 1. The enzyme conjugates medium- and long-chain fatty acyl-CoAs (C8:0 to C18:0) to glycine, with particular preference for oleoyl-CoA (C18:1-CoA); it shows no activity toward C22:6-CoA or chenodeoxycholoyl-CoA, nor toward serine or alanine 1. N-acyl glycines possess antinociceptive, anti-inflammatory, and antiproliferative properties and activate G-protein-coupled receptors 1. GLYATL2 localizes to the endoplasmic reticulum and is highly expressed in salivary gland and trachea, with expression also detected in spinal cord and skin fibroblasts 1. In disease contexts, GLYATL2 emerges as a potential biomarker across multiple malignancies: it was downregulated in type 2 diabetes patients 2, included in prognostic signatures for breast cancer 3 and early-stage lung squamous cell carcinoma 4, and identified as an ETV1 target gene in prostate cancer where its suppression by the small-molecule inhibitor YK-4-279 reduced tumor metastasis 5. Additionally, GLYATL2 is a Moll gland-enriched gene in the human eyelid, supporting the gland's specialized metabolic and secretory function 6.